-
Something wrong with this record ?
Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training
M. Srp, V. Capek, O. Gal, EK. Havrdova, R. Jech, R. Korteova, K. Novotna, E. Ruzicka, H. Ruzickova, B. Srpova, M. Hoskovcova
Language English Country Netherlands
Document type Journal Article
- MeSH
- Adult MeSH
- Respiratory Muscles MeSH
- Middle Aged MeSH
- Humans MeSH
- Resistance Training * MeSH
- Multiple Sclerosis * MeSH
- Muscle Strength MeSH
- Healthy Volunteers MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The efficacy of expiratory muscle strength training (EMST) in patients with multiple sclerosis (MS) is controversial. The current study's primary objective was to test the effects of a progressive and intensive 12 week home based EMST program on expiratory muscle strength and voluntary cough strength. The secondary objective was to determine the retention of EMST benefits. METHODS: Thirty-five severely disabled MS patients (relapsing-remitting MS, n = 15; primary progressive MS, n = 5; secondary progressive MS, n = 15) with Expanded Disability Status Scale (EDSS) 5.0 - 7.0 were included in the study. Within 36 weeks, patients completed 12 weeks of a non-training period, 12 weeks of EMST and 12 weeks of a detraining period. Maximal expiratory pressure (PEmax) and voluntary peak cough flow (vPCF) were assessed 4 times: at week 0 (baseline), week 12 (pre-training), week 24 (post-training), and week 36 (post-detraining). MS patients included in the study were compared to age- and sex-matched healthy subjects. In the healthy controls, the PEmax and vPCF were assessed once to obtain normative data. RESULTS: Twenty-six patients completed the training period (mean age 52.7 ± 10.2, EDSS 5.9 ± 0.6) and were compared to 26 sex- and age-matched healthy subjects (mean age 53.5 ± 5.8). Patients with MS had a lower PEmax (p = 0.002) and vPCF (p = 0.022) at baseline than the healthy control group. In training period, the PEmax and vPCF increased (p = 0.0000; effect size: d = 0.94 and p = 0.0036; d = 0.57 respectively) in comparison with the non-training period (p = 0.0692; d = -0.36 and p = 0.5810; d = 0.11 respectively). Following the 12 weeks detraining period, the PEmax and vPCF declined but remained 16.7% and 5.5% respectively above the pre-training values. No differences were observed in the PEmax and vPCF between the MS group at the post-training and post-detraining timepoint and the healthy control group normative values. CONCLUSIONS: EMST improves expiratory muscle strength and voluntary cough strength in severely disabled MS patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003623
- 003
- CZ-PrNML
- 005
- 20240903113231.0
- 007
- ta
- 008
- 220113e20210805ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.msard.2021.103187 $2 doi
- 035 __
- $a (PubMed)34388534
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Srp, Martin $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic. Electronic address: martin.srp@vfn.cz
- 245 10
- $a Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training / $c M. Srp, V. Capek, O. Gal, EK. Havrdova, R. Jech, R. Korteova, K. Novotna, E. Ruzicka, H. Ruzickova, B. Srpova, M. Hoskovcova
- 520 9_
- $a BACKGROUND: The efficacy of expiratory muscle strength training (EMST) in patients with multiple sclerosis (MS) is controversial. The current study's primary objective was to test the effects of a progressive and intensive 12 week home based EMST program on expiratory muscle strength and voluntary cough strength. The secondary objective was to determine the retention of EMST benefits. METHODS: Thirty-five severely disabled MS patients (relapsing-remitting MS, n = 15; primary progressive MS, n = 5; secondary progressive MS, n = 15) with Expanded Disability Status Scale (EDSS) 5.0 - 7.0 were included in the study. Within 36 weeks, patients completed 12 weeks of a non-training period, 12 weeks of EMST and 12 weeks of a detraining period. Maximal expiratory pressure (PEmax) and voluntary peak cough flow (vPCF) were assessed 4 times: at week 0 (baseline), week 12 (pre-training), week 24 (post-training), and week 36 (post-detraining). MS patients included in the study were compared to age- and sex-matched healthy subjects. In the healthy controls, the PEmax and vPCF were assessed once to obtain normative data. RESULTS: Twenty-six patients completed the training period (mean age 52.7 ± 10.2, EDSS 5.9 ± 0.6) and were compared to 26 sex- and age-matched healthy subjects (mean age 53.5 ± 5.8). Patients with MS had a lower PEmax (p = 0.002) and vPCF (p = 0.022) at baseline than the healthy control group. In training period, the PEmax and vPCF increased (p = 0.0000; effect size: d = 0.94 and p = 0.0036; d = 0.57 respectively) in comparison with the non-training period (p = 0.0692; d = -0.36 and p = 0.5810; d = 0.11 respectively). Following the 12 weeks detraining period, the PEmax and vPCF declined but remained 16.7% and 5.5% respectively above the pre-training values. No differences were observed in the PEmax and vPCF between the MS group at the post-training and post-detraining timepoint and the healthy control group normative values. CONCLUSIONS: EMST improves expiratory muscle strength and voluntary cough strength in severely disabled MS patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a zdraví dobrovolníci pro lékařské studie $7 D064368
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a roztroušená skleróza $7 D009103
- 650 _2
- $a svalová síla $7 D053580
- 650 12
- $a odporový trénink $7 D055070
- 650 _2
- $a dýchací svaly $7 D012132
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Capek, Vaclav $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Gal, Ota $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Havrdova, Eva Kubala $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Jech, Robert $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Korteova, Rebeka $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Novotna, Klara $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Ruzicka, Evzen $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Ruzickova, Hana $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 700 1_
- $a Srpová, Barbora $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic $7 xx0321726
- 700 1_
- $a Hoskovcova, Martina $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Katerinska 30, 128 21 Prague 2, Czech Republic
- 773 0_
- $w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 55 (20210805), s. 103187
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34388534 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20240903113228 $b ABA008
- 999 __
- $a ok $b bmc $g 1751169 $s 1154772
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 55 $c - $d 103187 $e 20210805 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
- LZP __
- $a Pubmed-20220113